EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects

Ya-Ruo Lei, Xian-Lu He, Jun Li, Chun-Fen Mo

Frontiers in Bioscience-Landmark · 2024

DOI: 10.31083/j.fbl2902052 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Ya-Ruo Lei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Chengdu Medical College, 610500 Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Project of Chengdu Health and Family Planning Commission, Department of Science and Technology of Sichuan Province (CN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary liver cancer is one of the most common malignant tumors with high mortality and increasing incidence worldwide. Currently, chemotherapy is an important comprehensive treatment for moderate or advanced liver cancer. Despite the effective therapeutic effects initially achieved by chemotherapy, the high phenotypic and molecular heterogeneity of liver cancer cells facilitates resistance to conventional chemotherapy or targeted therapy and even leads to multidrug resistance (MDR), which is one of the major obstacles for clinical chemotherapy. Drug resistance exhibits multiple and complex molecular mechanisms to antagonize therapy under pharmacological pressure, including overexpression of drug efflux transporters, downstream adaptive response (such as apoptosis, autophagy, and endoplasmic reticulum stress), dysfunction of DNA damage repair (DDR), epigenetic modification, tumor microenvironment (TME) as well as extracellular matrix (ECM). In this paper, we summarize the recent research progress and intervention strategies for drug resistance in hepatocellular carcinoma (HCC), which will provide a promising therapeutic strategy for overcoming MDR in liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansDrug Resistance, NeoplasmDrug Resistance, MultipleApoptosisTumor Microenvironment

Stichwörter der Autor:innen

chemotherapyhepatocellular carcinomaimmunotherapymultidrug resistancetargeted therapytumor microenvironment

Autor:innen und Institutionen

  • Department of Immunology, School of Basic Medical Sciences, Chengdu Medical College, 610500 Chengdu, Sichuan, China.
  • Department of General Surgery, Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), 610083 Chengdu, Sichuan, China.
  • Department of Gastroenterology, First Affiliated Hospital of Chengdu Medical College, 610500 Chengdu, Sichuan, China.

Förderung

  • National Natural Science Foundation of China
  • Project of Chengdu Health and Family Planning Commission
  • Department of Science and Technology of Sichuan Province (CN)
  • Disciplinary Construction Innovation Team Foundation of Chengdu Medical College

Zitieren

APA

Lei, Y. R., He, X. L., Li, J., & Mo, C. F. (2024). Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2902052

Vancouver

Lei YR, He XL, Li J, Mo CF. Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2902052

BibTeX
@article{Lei2024,
  author = {Lei, Ya-Ruo and He, Xian-Lu and Li, Jun and Mo, Chun-Fen},
  title = {Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  doi = {10.31083/j.fbl2902052}
}
Kostenlos starten →